Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**枳实总黄酮片** is an oral Chinese botanical medicine developed and manufactured by Jiangxi Qingfeng Pharmaceutical for functional dyspepsia, including postprandial distress symptoms such as postprandial fullness, early satiety, epigastric burning, and epigastric pain. It contains a standardized total flavonoid glycoside extract from immature *Citrus aurantium* fruit, with naringin and neohesperidin among representative constituents. The product is marketed in China under the brand **奥兰替** and was approved by the National Medical Products Administration on October 19, 2023. ([baike.baidu.com](https://baike.baidu.com/item/%E6%9E%B3%E5%AE%9E%E6%80%BB%E9%BB%84%E9%85%AE%E7%89%87/63661551))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 枳实总黄酮片.